Fresenius Medical Care AG

Fresenius Medical Care AG

21.86
USD
-0.17
(-0.77%)
2.24EPS
13.15P/E
11.65BMarket Cap
Feb 23Next Earn

Total Valuation

USD

As of September 30, 2026, Fresenius Medical Care AG carries a market capitalization of 11.65B, placing it among publicly traded companies globally. Its enterprise value stands at 23.40B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap11.65B
Enterprise Value23.40B

Important Dates

Fresenius Medical Care AG's next confirmed earnings release is scheduled for February 23, 2027.

Earnings Date2/23/2027

Share Statistics

As of September 30, 2026, Fresenius Medical Care AG has 520.71M shares outstanding.

Shares Outstanding520.71M

Valuation Ratios

As of September 30, 2026, Fresenius Medical Care AG trades at a trailing price-to-earnings ratio of 13.15. The price-to-sales ratio is 0.56, and the price-to-book ratio stands at 0.80.

PE Ratio13.15
PS Ratio0.56
PB Ratio0.80
P/TBV Ratio-4.14
P/FCF Ratio6.03
P/OCF Ratio3.75

Enterprise Valuation

As of September 30, 2026, Fresenius Medical Care AG trades at an EV/EBITDA multiple of 6.14 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.06 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 11.94 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Fresenius Medical Care AG trades at an EV/FCF ratio of 9.86, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 23.40B versus a market cap of 11.65B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.06
EV / EBITDA6.14
EV / EBIT11.94
EV / FCF9.86

Financial Position

As of September 30, 2026, Fresenius Medical Care AG maintains a current ratio of 0.99, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 79.13, indicating elevated leverage, while an interest coverage ratio of 8.68 demonstrates adequate ability to service its debt obligations.

Current Ratio0.99
Quick Ratio0.62
Debt / Equity79.13
Debt / EBITDA3.24
Interest Coverage8.68

Financial Efficiency

USD

Over the twelve months ended September 30, 2026, Fresenius Medical Care AG posted a return on equity (ROE) of 6.39, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.41 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.64, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.51, useful for judging operating efficiency across full business cycles. The company generates approximately 198,854.03 in revenue per employee across its workforce of 111,024.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.37 indicates how many times Fresenius Medical Care AG sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)6.39
Return on Assets (ROA)2.64
Return on Invested Capital (ROIC)5.41
Return on Capital Employed (ROCE)3.51
Revenue Per Employee198,854.03
Employee Count111,024.00
Inventory Turnover6.37

Taxes

USD

Over the twelve months ended September 30, 2026, Fresenius Medical Care AG recorded 359.13M in income tax expense. That works out to an effective tax rate of 22.61, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.59B, leaving 932.52M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax359.13M
Effective Tax Rate22.61

Stock Price Statistics

USD

As of the close on November 16, 2026, Fresenius Medical Care AG's stock has declined approximately 6.54% over the past 52 weeks. The 50-day moving average sits at 22.28, while the 200-day moving average is 22.90.

52-Week Price Change-6.54%
50-Day Moving Average22.28
200-Day Moving Average22.90

Income Statement

USD

Over the twelve months ended September 30, 2026, Fresenius Medical Care AG generated 22.08B in revenue and converted that into 932.52M in net income, yielding earnings per share of 2.24. EBITDA reached 3.81B, while operating income came in at 2.19B.

Revenue22.08B
Gross Profit5.84B
Operating Income2.19B
Pretax Income1.59B
Net Income932.52M
EBITDA3.81B
EBIT1.96B
Earnings Per Share (EPS)2.24

Balance Sheet

USD

As of September 30, 2026, Fresenius Medical Care AG holds 1.68B in cash and equivalents against 12.34B in total debt, resulting in a net debt position of 7.30B. Total book value stands at 14.50B, with working capital of -74.35M providing operational flexibility.

Cash & Cash Equivalents1.68B
Total Debt12.34B
Net Debt7.30B
Equity (Book Value)14.50B
Book Value Per Share27.85
Working Capital-74.35M

Cash Flow

USD

Fresenius Medical Care AG produced 3.27B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -1.24B in capital expenditures, free cash flow totaled 2.03B - equivalent to 3.71 per share.

Operating Cash Flow3.27B
Capital Expenditures-1.24B
Free Cash Flow2.03B
FCF Per Share3.71

Margins

Over the twelve months ended September 30, 2026, Fresenius Medical Care AG posted a gross margin of 26.46, reflecting its pricing power and cost economics. The operating margin of 9.93 and net profit margin of 4.22 provide insight into operational efficiency.

Gross Margin26.46
Operating Margin9.93
Pretax Margin7.20
Profit Margin4.22
EBITDA Margin17.26

Dividends & Yields

Over the twelve months ended September 30, 2026, Fresenius Medical Care AG paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 16.59, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 19.24, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Fresenius Medical Care AG shareholders.

Shareholder Yield19.24
FCF Yield16.59

Stock Splits

Fresenius Medical Care AG's most recent stock split took place on December 4, 2012 with a 1:2 split ratio.

Last Split Date12/4/2012
Split Ratio1:2

Scores

As of September 30, 2026, Fresenius Medical Care AG has an Altman Z-Score of 3.00, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.00